Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Ogden, UT
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Ogden, UT
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
West Jordan, UT
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
West Jordan, UT
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Charlottesville, VA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Chesapeake, VA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Chesapeake, VA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Danville, VA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Danville, VA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Fairfax, VA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Richmond, VA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Suffolk, VA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Suffolk, VA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Bellevue, WA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Bellevue, WA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Seattle, WA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Spokane, WA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Saint Petersburg, FL
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Ocean Springs, MS
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Ocean Springs, MS
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Kettering, OH
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Kettering, OH
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Downingtown, PA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Downingtown, PA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Corsicana, TX
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Corsicana, TX
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
mi
from
Berlin,
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
mi
from
Berlin,
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
Mayo Clinic
mi
from
Scottsdale, AZ
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
Colon and Rectal Medical Services
mi
from
Los Angeles, CA
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
Colon and Rectal Medical Services
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
University of California, Irvine Medical Center
mi
from
Orange, CA
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
Galliano Private Practice
mi
from
Port Charlotte, FL
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
Galliano Private Practice
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
USF Health
mi
from
Tampa, FL
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
USF Health
mi
from
Tampa, FL
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
North Pinellas Surgical Institute
mi
from
Tarpon Springs, FL
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
North Pinellas Surgical Institute
mi
from
Tarpon Springs, FL
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
Cleveland Clinic Florida Health
mi
from
Weston, FL
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
Cleveland Clinic Florida Health
mi
from
Weston, FL
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
Emory University
mi
from
Atlanta, GA
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
Georgia Regents Research Institute
mi
from
Augusta, GA
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
Georgia Regents Research Institute
mi
from
Augusta, GA
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
Iowa Clinic
mi
from
Des Moines, IA
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
Iowa Clinic
mi
from
Des Moines, IA
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
Colon and Rectal Surgery Associates, Ltd
mi
from
Minneapolis, MN
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
Colon and Rectal Surgery Associates, Ltd
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
Colon and Rectal Surgery, Inc
mi
from
Omaha, NE
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
Colon and Rectal Surgery, Inc
mi
from
Omaha, NE
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
North Shore Long Island Jewish Health Systems
mi
from
Huntington, NY
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
North Shore Long Island Jewish Health Systems
mi
from
Huntington, NY
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
NYU Langone Medical Center
mi
from
New York, NY
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
Mount Sinai Hospital
mi
from
New York, NY
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
Cleveland Clinic Foundation Digestive Disease Institute
mi
from
Cleveland, OH
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
Cleveland Clinic Foundation Digestive Disease Institute
mi
from
Cleveland, OH
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
Colon and Rectal Research Foundation
mi
from
Allentown, PA
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
Colon and Rectal Research Foundation
mi
from
Allentown, PA
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
Drexel University College of Medicine
mi
from
Philadelphia, PA
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
Drexel University College of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated:  12/8/2017
University of Vermont Medical Center
mi
from
Burlington, VT
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
Status: Enrolling
Updated: 12/8/2017
University of Vermont Medical Center
mi
from
Burlington, VT
Click here to add this to my saved trials
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated:  12/8/2017
Wilmax Clinical Research, Inc.
mi
from
Mobile, AL
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated: 12/8/2017
Wilmax Clinical Research, Inc.
mi
from
Mobile, AL
Click here to add this to my saved trials
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated:  12/8/2017
Center for Clinical Research
mi
from
Fair Oaks, CA
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated: 12/8/2017
Center for Clinical Research
mi
from
Fair Oaks, CA
Click here to add this to my saved trials
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated:  12/8/2017
Roy O. Kroeker, DPM , Inc.
mi
from
Fresno, CA
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated: 12/8/2017
Roy O. Kroeker, DPM , Inc.
mi
from
Fresno, CA
Click here to add this to my saved trials
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated:  12/8/2017
Foot and Ankle Clinic
mi
from
Los Angeles, CA
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated: 12/8/2017
Foot and Ankle Clinic
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated:  12/8/2017
Brian O'Carroll, DPM, Inc.
mi
from
Pismo Beach, CA
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated: 12/8/2017
Brian O'Carroll, DPM, Inc.
mi
from
Pismo Beach, CA
Click here to add this to my saved trials
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated:  12/8/2017
UCLA Medical Center - Olive View
mi
from
Sylmar, CA
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated: 12/8/2017
UCLA Medical Center - Olive View
mi
from
Sylmar, CA
Click here to add this to my saved trials
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated:  12/8/2017
Orange County Research Center
mi
from
Tustin, CA
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated: 12/8/2017
Orange County Research Center
mi
from
Tustin, CA
Click here to add this to my saved trials
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated:  12/8/2017
Advanced Research Institute of Miami
mi
from
Homestead, FL
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated: 12/8/2017
Advanced Research Institute of Miami
mi
from
Homestead, FL
Click here to add this to my saved trials
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated:  12/8/2017
UF Health Orthopaedic Surgery Clinic
mi
from
Jacksonville, FL
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus
Status: Enrolling
Updated: 12/8/2017
UF Health Orthopaedic Surgery Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials